Community rallies behind local man seeking kidney donor at ‘Adam's March for a Match'
NORTHAMPTON, Mass. (WWLP) – People from all over western Massachusetts came together to support a local man in his battle with kidney failure.
Friends, family, and the community gathered at Look Park on Sunday for Adam's March for a Match, walking to support Adam Gagne as he battles Stage 5 kidney failure.
'Groovin' with Garrett' fundraiser for local man who was paralyzed in skiing accident
'I created a video telling his story and what we needed, and then I worked with two of his really good friends, longtime friends, Sue and Eric Dibrinkisi,' said David Jeffway, Adam's March for a Match organizer. 'We decided we needed to rally the community behind him because he has been such a big part of this community.'
Adam was unable to be in attendance, as he has been in the hospital due to complications, but he was present on a video call. People were able to speak with Adam, sharing how he impacted their lives and adding written messages to his support board.
Adam Gagne made a huge impact on his community, as he served as Scout Master for over 30 years. Now his scouts throughout the years are giving back to him.
'Scouting and obtaining that rank of Eagle is all about giving back and helping other people at all times, which is part of the Scout oath,' said Jeffway, who served as an Eagle Scout under Gagne. 'This is all of that on display. It is not just through the words, it's exactly what we learned in scouting.'
The event was also catered by Jake's in Northampton. The restaurant's owners, Christopher Ware and Alexander Washut, were also Eagle Scouts under Gagne.
'He was like an older brother, more so than a Scout Master, if you will,' Ware said. 'It was really a great time in our lives, so when we heard he needs this kidney, we thought we want to help him any way we could.'
Jeffway said the goals of the event are to find a living donor, raise money for Gagne and his family, and show him just how many people care about him. For more information on how you can become a living donor and test to see if you are a match for Adam, visit baystatehealth.org/living-donor.
WWLP-22News, an NBC affiliate, began broadcasting in March 1953 to provide local news, network, syndicated, and local programming to western Massachusetts. Watch the 22News Digital Edition weekdays at 4 p.m. on WWLP.com.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Holyoke Medical Center recognized for equitable care efforts
HOLYOKE, Mass. (WWLP) – Holyoke Medical Center, located on Beech Street, has achieved a health care equity certification. Easthampton aims to enhance transparency with new public records management Holyoke Medical Center was awarded the Joint Commission's Health Care Equity Certification for excellence in its efforts to provide equitable care, treatment, and services. The center demonstrated that it has established processes to decrease health care disparities within its patient populations. The center underwent an onsite review on May 13th, and during the visit, The Joint Commission evaluated compliance with certification standards under the following terms: Leadership Collaboration Data collection Provision of care Performance improvement Another way Holyoke Medical Center is improving health equity is by collecting data from patients and offering additional screening tools, which gives them a better understanding of the patient population, as well as insights to improve patient care, enhance treatment protocols, and provide education to specific populations. 'Holyoke Medical Center is proud to be recognized for its efforts to provide equitable health care to everyone,' said Spiros Hatiras, President and CEO of Holyoke Medical Center and Valley Health Systems. 'This certification is a testament to our team members who provide high quality, compassionate care to all of our patients, every day.' 'Providing equitable health care and reducing barriers to care is not new to Holyoke Medical Center,' added Sr. Vice President and Chief Quality Officer Avadhoot Gokhale. 'We have a specific Health Equity Strategic Plan to guide our organization in addressing the needs of our community. These initiatives have been ongoing for years and are identified in our Community Health Needs Assessments including free transportation to health care services, access to nutritious food, access to health insurance, workforce development, and a myriad of other services.' 'Health Care Equity Certification distinguishes those organizations that have made health care equity a strategic priority and those that collaborate with patients, families, caregivers and external organizations to help translate equitable health care into better health outcomes,' says Ken Grubbs, DNP, MBA, RN, executive vice president of Accreditation and Certification Operations and chief nursing officer, The Joint Commission. 'We commend Holyoke Medical Center for using The Joint Commission's certification process to promote that all its patient populations receive access to equitable care, treatment and services.' WWLP-22News, an NBC affiliate, began broadcasting in March 1953 to provide local news, network, syndicated, and local programming to western Massachusetts. Watch the 22News Digital Edition weekdays at 4 p.m. on Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
2 hours ago
- Yahoo
Cardiovascular Tailwind Boosts BSX: Here's How to Play the Stock
Boston Scientific BSX, a prominent global player in cardiovascular technology, is well-positioned to capitalize on the robust expansion of the cardiovascular devices market. According to a MarketsandMarkets report, this market was valued at $72.83 billion in 2023 and is expected to witness a strong CAGR of 7.3% between 2024 and 2029. With its portfolio of Cardiology and Peripheral Interventions products, Boston Scientific is set to benefit significantly from this upward trend. The booming cardiovascular devices market, driven by aging demographics, minimally invasive procedures, and tech innovation, is propelling Boston Scientific's top-line growth, product leadership and stronger profitability. These tailwinds were clearly reflected in the company's robust first-quarter 2025 performance and raised full-year 2025 guidance. In the past year, Boston Scientific's shares have skyrocketed roughly 31.8%, outpacing the broader Medical Product industry and the S&P 500 benchmark, which have improved about 8.9% and 11.9%, respectively. During this time, Boston Scientific has also outpaced key peers such as Abbott Laboratories ABT and Medtronic MDT. While Abbott, known for its structural heart, cardiac rhythm management, and diagnostics products, gained 24.2%, Medtronic, known for heart valves and coronary stents, advanced 5.1%. Image Source: Zacks Investment Research Strong Q1: In the first quarter of 2025, Boston Scientific's revenues were up 22.2% on an operational basis (at a constant exchange rate or CER). The Cardiovascular segment sales were up 26.2% year over year. Within this, Cardiology and Peripheral Interventions businesses' sales grew 31.2% and 7.4%, respectively, year over year. U.S. revenues rose 31%, driven by double-digit growth in most business units. Japan and China also delivered strong results, particularly in EP. Boston Scientific reported adjusted earnings per share (EPS) of $0.75, up 34% year over year. The company's revenues and EPS rose due to exceptional top-line growth across key franchises, especially in EP and structural heart, combined with improved margin performance and disciplined cost management. Cardiovascular Steals Spotlight: Boston Scientific's Electrophysiology business is rapidly expanding its global market share, with first-quarter 2025 organic growth surging 145%, positioning BSX as the number two player in the space. This growth is largely driven by strong commercial adoption of FARAPULSE, the company's flagship Pulsed Field Ablation ('PFA') system, which is gaining traction through global demand, new account expansions, and ongoing clinical studies like AVANT GUARD and Elevate PF. Meanwhile, Boston Scientific's structural heart portfolio is also performing well, with WATCHMAN sales up 24% year over year, aided by DRG-enabled procedural growth. Next-gen versions — WATCHMAN FLX and FLX Pro — are accelerating adoption, while trials like CHAMPION-AF and OPTION A aim to expand the device's global market potential. For full-year 2025, Boston Scientific raised its organic revenue growth guidance to 12- 14% (from 10-12%) and now expects adjusted EPS of $2.87-$2.94, representing 14-17% year-over-year growth. Reported revenue growth is projected at 15-17%, including contributions from recent acquisitions like Axonics and Intera Oncology. Adjusted operating margin is expected to expand 50-75 basis points, driven by strong product mix, notably FARAPULSE and WATCHMAN, and cost efficiencies. Segmentally, Cardiology continues to lead growth, with Endoscopy and Neuromodulation expected to outperform markets and Urology affected modestly by supply constraints. The Zacks Consensus Estimate for Boston Scientific's 2025 sales and EPS implies a year-over-year improvement of 16.4% and 15.9%, respectively. The bottom-line estimates have moved northward in the past 60 days. Image Source: Zacks Investment Research Boston Scientific continues to face a challenging business environment, thanks to industry-wide macroeconomic pressures, including geopolitical tensions, global supply-chain disruptions, and labor market instability. International conflicts and retaliatory trade actions have increased global risks, while volatile financial markets and fluctuating prices for goods and services are squeezing profitability. Sustained macroeconomic pressures may make it more difficult for the company to manage operating expenses effectively. Tariffs are expected to have a $200 million impact in 2025, which, although planned to be offset through sales growth, cost controls and FX benefits, underscores the heightened complexity of the current environment. With a forward five-year price-to-earnings (P/E) of 33.31X, Boston Scientific's shares are trading at a premium compared with the industry average of 21.29X. It has a Value Score of D at present. Image Source: Zacks Investment Research Meanwhile, MDT's five-year price-to-earnings (P/E) of 15.63X is lower than the industry average. Considering Boston Scientific's strong operational performance, leadership in fast-growing cardiovascular segments like Electrophysiology and Structural Heart, and promising pipeline of developments, the company is clearly executing well on both growth and profitability fronts. With projected double-digit revenue and earnings growth, BSX is poised to continue delivering shareholder value, even amid a complex macroeconomic backdrop and tariff headwinds. The stock has excelled both the industry and its peers, and its estimates are likely to continue to trend upward in the near term. Henceforth, the current BSX shareholders may find it prudent to stay invested. Boston Scientific carries a Zacks Rank #3 (Hold) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
4 hours ago
- Yahoo
BioPorto A/S Announces the Appointment of a New CEO as Part of its Succession Planning Strategy
June 10, 2025Announcement no. 16 BioPorto A/S Announces the Appointment of a New CEO as Part of its Succession Planning Strategy COPENHAGEN, DENMARK and BOSTON, MA, USA, June 10, 2025, (GLOBE NEWSWIRE) - BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR) today announced the appointment of Carsten Buhl as Chief Executive Officer (CEO) of BioPorto A/S and its subsidiaries, effective 1 September 2025, as part of the Company's succession planning strategy. BioPorto's current CEO, Peter Mørch Eriksen, will remain in his position until 1 September 2025. Following this date, Peter Mørch Eriksen will support the incoming CEO during the transition period to ensure a smooth and effective onboarding process. Carsten Buhl has spent more than 25 years in the MedTech/life science industries, recently as President of Americas at WSAudiology and part of its executive management. Further, Carsten has experience from senior leadership positions at Natus Medical Inc, Ambu and GN Store Nord. Jens Due Olsen, Chair of BioPorto, stated: "I am pleased to welcome Carsten Buhl to BioPorto. Carsten will be instrumental in launching ProNephro AKI (NGAL)™ in the US market, driving revenue growth and finalizing the clinical studies & submitting an FDA application for adult use in 2026. With a strong background in MedTech/life science, Carsten has a proven track record of driving growth, innovation, and operational excellence. Carsten will be a solid addition to the BioPorto team.' Carsten Buhl, BioPorto's incoming CEO, commented: 'I am excited to join BioPorto at this amazing point in its journey, and look forward together with the BioPorto team to materialize the full potential of the Company's biomarker tests within kidney health, critical tests that can improve the clinical and economic outcomes for patients, providers, and healthcare ecosystem globally." Jens Due Olsen added: 'I want to extend my gratitude to and thank Peter for his dedication and important contributions to BioPorto. During this second tenure, significant milestones have been achieved — including the development of a comprehensive Corporate Strategy Plan, securing revenue growth, preparation for the commercial launch of ProNephro AKI (NGAL) in the US, advancement of the clinical trial for adult use, and securing successive critical financing rounds for the Company. These accomplishments have laid a robust foundation for BioPorto's continued growth and success.' To receive BioPorto's Company Announcements, Press Releases, Newsletters and other business relevant information, please sign up on Investor Relations Contacts Hanne S. Foss, Head of Investor Relations, BioPorto A/S, investor@ C: +45 26368918 About BioPorto BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company's tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem. The Company's flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide. BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit Forward looking statement disclaimer Certain statements in this news release are not historical facts and may be forward-looking statements. Forward-looking statements include statements regarding the intent, belief or current expectations with respect to the Company's expectations, intentions and projections regarding its future performance including the Company's Guidance for 2025; currency exchange rate fluctuations; anticipated events or trends and other matters that are not historical facts, including with respect to implementation of manufacturing and quality systems, commercialization of NGAL tests, and the development of future products and new indications; concerns that may arise from additional data, analysis or results obtained during clinical trials; and, the Company's ability to successfully market both new and existing products. These forward-looking statements, which may use words such as 'aim', 'anticipate', 'believe', 'intend', 'estimate', 'expect' and words of similar meaning, include all matters that are not historical facts. These forward-looking statements involve risks, and uncertainties that could cause the actual results of operations, financial condition, liquidity, dividend policy and the development of the industry in which the Company's business operates to differ materially from the impression created by the forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Given these risks and uncertainties, prospective investors are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of such statements and, except as required by applicable law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Factors that may impact BioPorto's success are more fully disclosed in BioPorto's periodic financial filings, including its Annual Report for 2024, particularly under the heading 'Risk Factors'. Attachment 2025 06 10 - Announcement no. 16 - UKError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
